MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco-25-02558

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025

New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System.

Khwaja Jahanzaib, Kirkwood Amy A, Milani Paolo, Yohannan Binoy, Theodorakakou Foteini, Weverling Flores, Di Simone Valeria, Ravichandran Sriram, Kumar Shaji, Petropoulos Ioannis, Mussinelli Roberta, Cohen Oliver, Oerlemans Marish I F J, Muchtar Eli, Stamatelopoulos Kimon, Lachmann Helen J, Gillmore Julian D, Briasoulis Alexandros, Gertz Morie, Whelan Carol, Venneri Lucia, Fontana Marianna, Mahmood Shameem, Schwotzer Rahel, Minnema Monique C, Dispenzieri Angela, Palladini Giovanni, Kastritis Efstathios, Wechalekar Ashutosh

СтатьяВалидационное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Outcomes in systemic light chain (AL) amyloidosis have improved with modern therapy limiting utility of existing risk stratification models. We validate a new staging system, incorporating longitudinal strain (LS) to the biomarker-based (NT-proBNP and Troponin-T) staging system in the contemporary treatment era (2015-2024).

METHODS

AL International Staging System (AL-ISS) was derived from a cohort of patients with AL amyloidosis from the UK National Amyloidosis Centre (2015-2019). The model was validated in patient cohorts from Europe (Greece, Italy, the Netherlands, and Switzerland), the United States (2015-2024), and the United Kingdom (2020-2024).

RESULTS

In total, 2,493 patients were included (derivation, n = 573; validation n = 1,920). In a multivariable model for the derivation cohort, LS ≥ -9% and cardiac biomarkers at previously validated thresholds (NT-proBNP 332 ng/L and 8,500 ng/L and high-sensitivity troponin T ≥ 50 ng/L) were independent poor prognostic factors stratifying patients into stages I, II, IIIA, IIIB, and IIIC. In the validation cohort, the patient stages were stage I: 317 (17%), II: 782 (41%), IIIA: 551 (29%), IIIB: 174 (9%), and IIIC: 96 (5%), respectively (first-line daratumumab treated: 826; 43%). With a median follow-up of 34 months, median overall survival (OS) was not reached (NR); estimated 1-year, 2-year, and 3-year OS was 82%, 74%, and 70% respectively. The median survival for stages I to II, IIIA, IIIB, and IIIC were NR, 67, 26, and 7 months (1-year OS IIIC 53% v 68% for IIIB in the daratumumab-treated patients), respectively (P < .001). External validation exhibited good predictive performance: 12-month calibration slope was 1.09, Harrell C 0.69, Royston D 1.19, and R2D 0.25. Stage IIIC independently discriminated the poorest outcome across all cohorts.

CONCLUSION

This defines and validates a new staging system from systemic AL amyloidosis with robust identification of an ultra-poor risk stage (IIIC) in contemporarily treated patients.

Для цитирования: Khwaja Jahanzaib, Kirkwood Amy A, Milani Paolo, Yohannan Binoy, Theodorakakou Foteini, Weverling Flores, Di Simone Valeria, Ravichandran Sriram, Kumar Shaji, Petropoulos Ioannis, Mussinelli Roberta, Cohen Oliver, Oerlemans Marish I F J, Muchtar Eli, Stamatelopoulos Kimon, Lachmann Helen J, Gillmore Julian D, Briasoulis Alexandros, Gertz Morie, Whelan Carol, Venneri Lucia, Fontana Marianna, Mahmood Shameem, Schwotzer Rahel, Minnema Monique C, Dispenzieri Angela, Palladini Giovanni, Kastritis Efstathios, Wechalekar Ashutosh. New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. DOI: 10.1200/jco-25-02558.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.